United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

RBC has upgraded MannKind (NASDAQ:MNKD) to outperform from sector perform, citing the company’s Tyvaso DPI royalty revenue opportunity and orphan lung pipeline. The investment bank estimates the ...

Dosage for transition from Tyvaso Inhalation Solution: see full labeling. Risk of symptomatic hypotension in those with low systemic arterial pressure. Hepatic insufficiency; titrate slowly.

Mosliciguat, targeting PH-ILD, could compete with Tyvaso ($433.8M in Q3 sales) through once-daily dosing and novel mechanism, pending Phase 2 results. The company maintains strong financials with ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions involving the company's common stock. On January 21, Benkowitz sold ...

If PH-ILD studies translate into the real world, the market opportunity for Liquidia is enormous. Where should we expect LQDA stock to be in the next few months? Find out.

At the moment, the only FDA-approved treatment for PH-ILD is United Therapeutics' Tyvaso inhaled prostacyclin analogue (treprostinil), which is delivered either using a nebuliser or as a DPI four ...

“At this year’s annual congress, we are delighted to share further findings that support long-term outcomes and dosing of Tyvaso DPI, as well as interim data from our PHINDER study that is ...

announced full enrollment of the TETON 1 study evaluating the use of Tyvaso® (treprostinil) inhalation solution (nebulized Tyvaso) for the treatment of idiopathic pulmonary fibrosis (IPF).

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or nebulized Tyvaso, for the treatment of idiopathic ...